Delpharm has acquired the Boucherville manufacturing plant owned by Sandoz Canada, in Québec. This plant is the largest sterile injectable production facility in Canada and provides medicines to the Canadian and U.S. healthcare systems, mostly hospitals. 

“We are proud to acquire this manufacturing facility in Boucherville, which represents our 2nd production site in Canada. This acquisition will allow us to propose sterile manufacturing to the North American market,” said Sébastien Aguettant, Delpharm’s Chairperson and CEO. “Over the year, Delpharm expertise has been growing and expanding its global footprint thanks to the new sites joining the network. We are thrilled to welcome aboard the Boucherville team and we look forward to working with them in order to provide a wide range of injectables for our customers that meet the most rigorous quality and reliability standards set by pharmaceutical regulatory authorities.” 

While all Sandoz Canada injectable products will be manufactured by Delpharm with the same high-quality formulations as before, Sandoz Canada remains the owner of the marketing authorizations and intellectual property and will continue to have commercial responsibility for all its products. Delpharm plans to invest in the site and pursue business development opportunities to grow the business.